AstraZeneca plc (AZN) Shares Bought by Oppenheimer Asset Management Inc.
Oppenheimer Asset Management Inc. lifted its position in AstraZeneca plc (NYSE:AZN) by 9.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 424,389 shares of the company’s stock after purchasing an additional 36,886 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in AstraZeneca were worth $14,378,000 at the end of the most recent quarter.
Other institutional investors have also recently added to or reduced their stakes in the company. WFG Advisors LP increased its holdings in shares of AstraZeneca by 36.0% in the second quarter. WFG Advisors LP now owns 3,716 shares of the company’s stock worth $127,000 after purchasing an additional 984 shares during the period. Bronfman E.L. Rothschild L.P. increased its holdings in shares of AstraZeneca by 71.2% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 4,252 shares of the company’s stock worth $145,000 after purchasing an additional 1,769 shares during the period. Quadrant Capital Group LLC increased its holdings in shares of AstraZeneca by 18.4% in the second quarter. Quadrant Capital Group LLC now owns 5,437 shares of the company’s stock worth $147,000 after purchasing an additional 846 shares during the period. Westport Asset Management Inc. bought a new position in shares of AstraZeneca in the second quarter worth $170,000. Finally, First Interstate Bank increased its holdings in shares of AstraZeneca by 10.3% in the second quarter. First Interstate Bank now owns 5,127 shares of the company’s stock worth $175,000 after purchasing an additional 480 shares during the period. 14.75% of the stock is currently owned by hedge funds and other institutional investors.
AstraZeneca plc (NYSE:AZN) opened at $32.09 on Thursday. The company has a market capitalization of $81,527.05, a price-to-earnings ratio of 7.68, a P/E/G ratio of 3.12 and a beta of 0.72. The company has a debt-to-equity ratio of 1.09, a current ratio of 0.94 and a quick ratio of 0.72. AstraZeneca plc has a 12 month low of $25.55 and a 12 month high of $35.60.
AZN has been the topic of several research analyst reports. Natixis raised shares of AstraZeneca from a “neutral” rating to a “buy” rating in a report on Wednesday, September 6th. Leerink Swann upped their price target on shares of AstraZeneca from $31.00 to $34.00 and gave the stock a “market perform” rating in a report on Monday, October 23rd. Credit Suisse Group raised shares of AstraZeneca from a “neutral” rating to an “outperform” rating in a report on Monday, October 16th. Argus reaffirmed a “buy” rating and issued a $35.00 price target on shares of AstraZeneca in a report on Friday, September 1st. Finally, Piper Jaffray Companies reissued a “buy” rating on shares of AstraZeneca in a research note on Wednesday, August 9th. Four analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have given a buy rating to the stock. AstraZeneca presently has a consensus rating of “Hold” and a consensus target price of $34.20.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).
Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.